Abolis is already a major success story in European industrial biotech, with a strong track record of strategic and financial performance, and an impressive client base. Icos Capital is proud to be part of this growth financing round, which should propel Abolis to the next level. Icos Capital, along with its corporate partners such as Nouryon and Bühler, looks forward … Read More